Single-Cell Reveal GALNT7-Dependent Ferroptosis Suppression as a Mechanism of Immunotherapy Resistance in Non-Small Cell Lung Cancer.

Summary

This multi-omics study identifies GALNT7 upregulation in ICB non-responding NSCLC and shows that GALNT7 suppresses ferroptosis programs. Genetic silencing of GALNT7 triggers ferroptotic death, downregulates SLC7A11/GPX4, upregulates ACSL4, reduces tumor growth in vivo, and enhances CD8 responses.

Key Findings

• GALNT7 is selectively upregulated in ICB non-responders and enriched in malignant epithelial cells.
• GALNT7 suppresses ferroptosis; its silencing induces ferroptotic death with lipid peroxidation and mitochondrial injury.
• GALNT7 loss reduces SLC7A11/GPX4 and increases ACSL4; in vivo knockdown reduces tumor growth and enhances CD8 responses.

Clinical Implications

While preclinical, the data support therapeutic strategies that downregulate GALNT7 or co-opt ferroptosis (e.g., GPX4/SLC7A11 modulation) to overcome ICB resistance in NSCLC.

Limitations

• Preclinical study; no prospective clinical validation of GALNT7-targeted strategies
• The abstract truncates some in vivo immune findings; full dataset details not available here

Future Directions

Design early-phase trials combining ICB with ferroptosis-augmenting agents or GALNT7 inhibitors; develop biomarkers to stratify patients by GALNT7/ferroptosis activity.